Trial Profile

A multi-center prospective single-arm trial for neoadjuvant chemotherapy with pyrotinib plus trastuzumab for HER2-positive breast cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pyrotinib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Trastuzumab
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use

04 Jun 2024 Results assessing relationship between PIK3CA mutations and survival in patients with human epidermal growth factor receptor 2 positive breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
02 Nov 2022 Results exploring relationship between tumor biomarkers and the postoperative pathological complete response, published in the British Journal of Cancer
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com